UBS Group upgraded shares of BioAge Labs (NASDAQ:BIOA – Free Report) to a hold rating in a research report report published on Sunday,Zacks reports.
A number of other equities research analysts have also recently issued reports on BIOA. Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a research note on Friday, July 31st. Weiss Ratings cut shares of BioAge Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. Roth Capital reiterated a “buy” rating and issued a $25.00 target price on shares of BioAge Labs in a research report on Wednesday, September 9th. BTIG Research reissued a “buy” rating and issued a $40.00 price target on shares of BioAge Labs in a research note on Tuesday, September 8th. Finally, Needham & Company LLC cut their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.
View Our Latest Research Report on BioAge Labs
BioAge Labs Price Performance
BioAge Labs (NASDAQ:BIOA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. On average, equities analysts anticipate that BioAge Labs will post -2.45 earnings per share for the current year.
Institutional Investors Weigh In On BioAge Labs
Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new stake in shares of BioAge Labs in the second quarter worth about $84,000. State of Wyoming purchased a new position in BioAge Labs during the 2nd quarter valued at about $154,000. Bank of Nova Scotia bought a new position in BioAge Labs during the 1st quarter valued at approximately $180,000. The Manufacturers Life Insurance Company bought a new position in BioAge Labs during the 2nd quarter valued at approximately $234,000. Finally, Engineers Gate Manager LP purchased a new stake in BioAge Labs in the 2nd quarter worth approximately $344,000.
About BioAge Labs
BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.
BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.
See Also
- Five stocks we like better than BioAge Labs
- Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.
